Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 5/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.44 |
| ▸ | PRKACA | P17612 | 3/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lophocladine A SCHEMBL24941905 | 0.75 | PARP1 (0.66) | PARP1DYRK1AAURKBJAK2FGFR1 | |
| SCHEMBL25252733 | 0.73 | PARP1 (0.56) | MAPTPARP1DYRK1AJAK2PIM1 | |
| SCHEMBL30476875 | 0.73 | PARP1 (0.56) | MAPTPARP1DYRK1AJAK2PIM1 | |
| SCHEMBL24759967 | 0.73 | PARP1 (0.56) | MAPTPARP1RPS6KA3DYRK1AAURKB | |
| SCHEMBL8802289 | 0.71 | DAO (0.47) | MAPTDAPK3PRKACARPS6KA3DYRK1A | |
| SCHEMBL6764983 | 0.71 | CYP3A4 (0.53) | MAPTPARP1DYRK1AALDH1A1KDM4E | |
| SCHEMBL30950905 | 0.70 | PARP1 (0.40) | PARP1PRKACAJAK2GSK3BALDH1A1 | |
| SCHEMBL24941862 | 0.70 | PARP1 (0.69) | PARP1DYRK1AAURKBJAK2FGFR1 | |
| SCHEMBL1049635 | 0.69 | ZAP70 (0.53) | MAPTPARP1DAPK3PRKACARPS6KA3 | |
| SCHEMBL30950938 | 0.69 | PARP1 (0.36) | MAPTPARP1DYRK1AJAK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023129933-A2 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | 858 THERAPEUTICS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059207-A1 | 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, METTL16, TPMT | MAPT 817/4885PARP1 3350/4885DAPK3 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.